LevelStock.com: Power3 Presents State of the Company Report at the Economic Development Partners Luncheon and Form 8-K for POWER 3 MEDICAL PRODUCTS INC

Power3 Medical Products, Inc.(OTCBB:PWRM) announced yesterday that Helen R. Park, Power3's Chief Executive Officer, presented a "State of the Company" report to a sell-out crowd at the Economic Development Partners luncheon held this past Tuesday, May 11, 2010 at the Woodlands Resort and Conference Center.

Ms. Park was the lead speaker at the event and was joined by several other notable speakers, including Joseph Podolski, President and CEO of Repros Therapeutics (NasdaqCM: RPRX), Arthur T. Sands, President and CEO of Lexicon Pharmaceuticals (NasdaqGM: LXRX - News), and Neil Warma, President and CEO of Opexa Therapeutics (NasdaqCM: OPXA). The report provided by Ms. Park was very similar to those recently presented by Bill Gates of Microsoft Corp (NasdaqGS: MSFT - News) and Warren Buffet of Berkshire Hathaway (NYSE: BRK-A - News) to members of the public.

Each of the presenters described the difficulties they have encountered during the recent economic downturn and the steps that they took to ensure their survival. They also described the current status of their technologies in the clinical trial lifestyle and their plans for these products once they reach commercialization.

"Power3 has taken a hard line approach to manage the resources and secure new capital to survive the economic down turn," stated Ms. Park. "We are delighted to be actively moving forward with our clinical trials for our Alzheimer's disease diagnostic tests and Parkinson's disease diagnostic tests. We have implemented a lean and mean approach to our work and the commercialization of our products which is serving us very well at the present time."

"We are delighted to have been selected by Economic Development Partners as a member of this prestigious panel of presenters," stated Ira Goldknopf, Ph.D., President and Chief Scientific Officer of Power3. "We are an integral part of the biotech community in the greater Houston area and are happy to share our success with the community and our peer biotechnology companies."

Power3 Medical Products

Power3 Medical Products, Inc. is a leading bio-technology company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease and amyotrophic lateral sclerosis (commonly known as ALS or Lou Gehrig's disease). Power3 applies proprietary methodologies to discover and identify protein biomarkers associated with diseases. Through these processes, Power3 has developed a portfolio of products including BC-SeraPro, a proteomic blood serum test for the early detection of breast cancer for which its has completed Phase I clinical trials, and NuroPro , a serum test for the detection of neurodegenerative diseases, including Alzheimer's, Parkinson's and ALS diseases, currently engaged in Phase II clinical trials. These products are designed to analyze proteins and their mutations to assess an individual's risk for developing disease later in life, a patient's likelihood of responding to a particular drug, a patient's risk of disease progression and disease recurrence, to measure a patient's exposure to drug therapy, to ensure optimal dosing and reduced drug toxicity.

For more information, please visit http://www.power3medical.com.

Safe Harbor Provision

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact contained herein, including, without limitation, statements regarding the company's future financial position, business strategy, budgets, projected revenues and costs, and plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "may," "will," "expects," "intends," "plans," "projects," "estimates," "anticipates," or "believes" or the negative thereof or any variation thereon or similar terminology or expressions. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from results proposed in such statements. Although the company believes that the expectations reflected in such forward-looking statements are reasonable, it can provide no assurance that such expectations will prove to have been correct. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors set forth in the company's Annual Report on Form 10-K for the year ended December 31, 2009 and its other filings and submissions with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date made. Except as required by law, the company assumes no obligation to update or revise any of the information contained in this press release.

Also filed yesterday, May 12th, 2010 PWRM.OB filied its Form 8-K

Form 8-K for POWER 3 MEDICAL PRODUCTS INC

12-May-2010

Termination of a Material Definitive Agreement, Other Events, Financ Item 1.02 Termination of a Material Definitive Agreement. On May 6, 2010, Power3 Medical Products, Inc., a New York corporation ("Power3″), exercised its right to terminate the Agreement and Plan of Merger (the "Merger Agreement"), dated February 9, 2010, by and among Power3, Power3 Acquisition Corp., a Delaware corporation and wholly-owned subsidiary of Power3 ("Merger Sub"), and StemTroniX, Inc., a Texas corporation ("StemTroniX"), pursuant to which Merger Sub was going to merge with and into StemTroniX, the separate corporate existence of Merger Sub was going to cease, and StemTroniX was going to continue as the surviving company and a wholly-owned subsidiary of Power3 (the "Merger").

Under the terms and conditions of the Merger Agreement, each outstanding share of StemTroniX common stock would have been converted into the right to receive fourteen and sixth-tenths (14.60) shares of Power3′s common stock, subject to certain adjustments as provided in the Merger Agreement.

Helen R. Park is currently the chairman of the board of directors and chief executive officer of Power3 and a shareholder of Power3. Ms. Park is also the chairman of the board of directors, president, chief financial officer and secretary of StemTroniX and a shareholder of StemTroniX.

The foregoing summary of the Merger Agreement does not purport to be complete and is qualified in its entirety by reference to the Merger Agreement which is attached hereto as Exhibit 99.1 and incorporated by reference herein.

Item 8.01. Other Events. On May 7, 2010, Power3 issued a press release announcing, in part, Power3′s decision to terminate the Merger Agreement. A copy of the press release is furnished herewith as Exhibit 99.2 and incorporated by reference herein.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

99.1 Agreement and Plan of Merger, dated February 9, 2010, by and among Power3, Merger Sub and StemTroniX (incorporated by reference to Exhibit 2.1 to the Current Report on Form 8-K filed with the SEC on February 11, 2010)

99.2 Press Release dated May 7, 2010

About LevelStock.com

We are an investor community and investors relations website specializing in emerging growth stocks in today's Hot Sectors and providing a platform of services for SmallCap, MicroCap, NanoCap Companies.

We encourage everyone to join our social media sites:

Free Subscription For Our Newsletters: http://www.levelstock.com/

FaceBook: http://www.facebook.com/group.php?gid=283660480870

Twitter: http://twitter.com/levelstock

LevelStock.com is not a registered investment advisor or broker-dealer. The information here is believed to be reliable, but not guaranteed to be accurate by LevelStock.com Please be advised that the information contained may or may not be complete and is solely for informational purposes only. Please read our full disclaimer for complete risks and disclosures http://levelstock.bondwaresite.com/news.php?viewStory=19

CONTACT: LevelStock.com e-mail: support@levelstock.com